期刊文献+

国外华法林抗凝管理模式现状及对我国抗凝管理的启示 被引量:13

Current status of warfarin anticoagulation management service in foreign countries and its enlightenment to China
原文传递
导出
摘要 华法林是临床上广泛应用的口服抗凝药物,设立抗凝门诊服务对华法林的规范化应用有着非常重要的作用。近年来,国外药师在医疗保健机构的推动下参与到抗凝管理中,结合新技术的开展应用形成系统化的抗凝服务体系,取得良好效果。而我国借鉴国外的模式和经验,已在部分医院建立了抗凝门诊,并取得一定成果。但抗凝门诊尚处于初步阶段,结合我国内地的实际情况开展适合我国国情的抗凝管理依然面临考验。本文通过综述国外抗凝门诊的模式现状及应用发展,旨在为中国内地抗凝门诊模式的完善提供借鉴。 Warfarin is an oral anticoagulant widely used in clinic and it is very important to establish the anti- coagulation outpatient service for the standardized application of warfarin. In recent years, foreign pharmacists participated in anticoagulant management driven by health care institutions, combined with the application of new technologies to form a systematic service system, and achieved good results. Drawing lessons from foreign models and experiences, we have established anticoagulation clinics in some hospitals in our country and achieved some results. However, as it is still in its preliminary stage, anticoagulant management suited to the national conditions of our country is still facing the test in light of the actual situation in the mainland of China. This article summarizes the current situation and application development of anticoagulant clinic in foreign countries, and aims to provide reference for the improvement of anticoagulation clinic in mainland of China.
作者 宋杲 李朝梅 杨雅清 钱懿轶 吴迪 翁稚颖 SONG Gao1, LI Chaomei1, YANG Yaqing1 ,QIAN Yiyi2, WU Di2, WENG Zhiying1(1School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, 650500, China ; 2 Department of Clinical Pharmacy, the First Affiliated Hospital of Kunming Medical Universit)
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2018年第3期222-225,共4页 Journal of Clinical Cardiology
基金 滇美分子药物联合研究中心(No:20151D001) 昆明医科大学大学生创新创业开放示范实验基地(No:J1301307434) 2016年云南省八大重点产业引领品牌专业临床药学专业(No:60116093802)
关键词 抗凝门诊 华法林 临床药师 抗凝管理模式 anticoagulant clinic warfarin clinical pharmacist anticoagulation management
  • 相关文献

参考文献10

二级参考文献62

  • 1张彦丽,王景红,顾媛媛,桂班月.华法林与中草药的相互作用[J].中国药物警戒,2011,8(1):41-45. 被引量:31
  • 2许俊堂.口服抗凝药的作用机制与临床应用(上)[J].中国医刊,2006,41(1):51-52. 被引量:22
  • 3HIRSH J, FUSTER V, ANSELL J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy[J]. Circulation, 2003, 107:1692-1711.
  • 4CHESEBRO J H, KNATTERUD G, ROBERTS R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous strepto- kinase. Clinical findings through hospital discharge [J]. Circulation, 1987, 76:142-154.
  • 5SINGER D E, CHANG Y, FANG M C, et al. Should patient characteristics influence target antieo- agulation intensity for stroke prevention in nonvalvu- lar atrial fibrillation? the ATRIA study[J]. Circ Cardiovasc Qual Outcomes, 2009, 2 : 297- 304.
  • 6APOSTOLAKIS S, LANE D A, GUO Y, et al. Per- formance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fi- brillation) study[J]. J Am Coll Cardiol, 2012, 60: 861-867.
  • 7SNIPELISKY D,KUSUMOTO F. Current strategies to mini-mize the bleeding risk of warfarin [ J]. J Blood Med, 2013(4):89-99.
  • 8朱国旺.我国房颤抗凝治疗极低[J].中国医药报,2013-11-7(06).
  • 9TESTA S, ALATRI A. Reorganisation of an anticoagulationclinic using a telemedicine system : description of the modeland preliminary results [ J]. Int Emerg Med,2006,1(1):24-29.
  • 10HART R G, PEARCE L A, AGUILAR M I. Meta-analysis:An- tithrombotic therapy to prevent stroke in patients who have nonval- vular aria| fibrillation [J]. Ann Intern Med, 2007,146 (12) : 857-867.

共引文献1477

同被引文献104

引证文献13

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部